Where does Neil Exter work?

Neil Exter is Board director at Cedilla Therapeutics, Inc. and Board director at Goldfinch BioPharma and Board director at Pliant Therapeutics.

What check size does Neil Exter write?

Neil Exter typically writes checks of $100K – $5M.

What boards does Neil Exter sit on?

Neil Exter holds tracked board seats at Cedilla Therapeutics, Inc., CytomX Therapeutics, Decibel Therapeutics, Element Science, Goldfinch BioPharma, Pliant Therapeutics, Revolution Medicines, Rhythm Pharmaceuticals.

Where did Neil Exter go to school?

Neil Exter studied at Harvard Business School (MBA); Stanford University (MS, Electrical Engineering); Cornell University (BS, Electrical Engineering).

Neil Exter

InvestorFounder

Board director at Cedilla Therapeutics, Inc. · Board director at Goldfinch BioPharma · Board director at Pliant Therapeutics

East Coast

Writes $100K – $5M checks · typically $1.5M

About

Neil Exter is a retired partner at Third Rock Ventures, which he joined in 2007, where he concentrated on the formation, development and strategy of new companies. He brings more than 30 years of operating, business development and strategy experience spanning emerging and established biotechnology and technology companies. He trained as an electrical engineer, earning degrees from Cornell and Stanford before completing an MBA at Harvard Business School.

Beyond investing

Education: Earned a B.S. in Electrical Engineering from Cornell University. Earned an M.S. in Electrical Engineering from Stanford University. Holds an MBA from Harvard Business School.

From Neil's own website — common ground for a warm intro.

Board director at Cedilla Therapeutics, Inc.

Intro paths

→

In turn, Neil can intro founders to Cedilla Therapeutics, Inc.'s investors below.

Cedilla Therapeutics, Inc.'s investors · 2

Casdin CapitalNew York · since 2021 Third Rock VenturesBoston · $100K – $5M checks · since 2020

Board director at Goldfinch BioPharma

Intro paths

→

In turn, Neil can intro founders to Goldfinch BioPharma's investors below.

Goldfinch BioPharma's investors · 1

Third Rock VenturesBoston · $100K – $5M checks · since 2020

Board director at Pliant Therapeutics

Intro paths

→

In turn, Neil can intro founders to Pliant Therapeutics's investors below.

Pliant Therapeutics's investors · 3

Agent CapitalWaltham Menlo VenturesSan Francisco · $1M – $20M checks Third Rock VenturesBoston · $100K – $5M checks · since 2018

Co-founders at Pliant Therapeutics

Bernard CoulieExecutive Officer, Director

Experience

Third Rock VenturesRetired Partnercurrent2025 — present
Third Rock VenturesPartner2007 — 2025
Alantos PharmaceuticalsChief Business Officer2006 — 2007
Millennium PharmaceuticalsVP Business Development2002 — 2006
MacGregorEVP2000 — 2001
Flexplay TechnologiesCEO1999 — 2000
Wang LabsVP Business Development1992 — 1999
Corporate DecisionsConsultant1991
Stellar ComputerProject Leader1986 — 1990
HPSales Development et al1979 — 1986

Education

Harvard Business SchoolMBA1990 — 1992
Stanford UniversityMS, Electrical Engineering1979 — 1981
Cornell UniversityBS, Electrical Engineering1977 — 1979
Francis LewisHS1971 — 1975

Deals · 7

Cedilla Therapeutics, Inc.Board seat

via Third Rock Ventures · filed Oct 2021 · $82.6M raise

Goldfinch BioPharmaBoard seat

via Third Rock Ventures · filed Jul 2020

Revolution MedicinesBoard seat

via Third Rock Ventures · filed Nov 2019 · $100.3M raise

Pliant TherapeuticsBoard seat

via Third Rock Ventures · filed Jul 2018 · $62.1M raise

Element ScienceBoard seat

via Third Rock Ventures · filed Aug 2016 · $25M raise

Rhythm PharmaceuticalsBoard seat

via Third Rock Ventures · filed Dec 2015 · $40M raise

CytomX TherapeuticsBoard seat

via Third Rock Ventures · filed Jan 2015 · $30M raise

Attribution from SEC filings, press coverage, and firm rosters.

Other disclosed investments

Board seats

Decibel Therapeutics

Per SEC Form D filings.

Frequently asked questions

Who is Neil Exter?: Neil Exter is a retired partner at Third Rock Ventures, which he joined in 2007, where he concentrated on the formation, development and strategy of new companies. He brings more than 30 years of operating, business development and strategy experience spanning emerging and established biotechnology and technology companies. He trained as an electrical engineer, earning degrees from Cornell and Stanford before completing an MBA at Harvard Business School.
Where does Neil Exter work?: Neil Exter is Board director at Cedilla Therapeutics, Inc. and Board director at Goldfinch BioPharma and Board director at Pliant Therapeutics.
What check size does Neil Exter write?: Neil Exter typically writes checks of $100K – $5M.
What boards does Neil Exter sit on?: Neil Exter holds tracked board seats at Cedilla Therapeutics, Inc., CytomX Therapeutics, Decibel Therapeutics, Element Science, Goldfinch BioPharma, Pliant Therapeutics, Revolution Medicines, Rhythm Pharmaceuticals.
Where did Neil Exter go to school?: Neil Exter studied at Harvard Business School (MBA); Stanford University (MS, Electrical Engineering); Cornell University (BS, Electrical Engineering).